[{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Fucose","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avalo Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for L-Fucose

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The active pharmaceutical ingredient (API) in AVTX-803 is L-fucose an oral formulation of L-fucose that enhances fucosylation of proteins in the absence of a functioning GDP-fucose transporter, partially restoring protein function.

                          Brand Name : AVTX-803

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 02, 2022

                          Lead Product(s) : L-Fucose

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank